Belite Bio to host virtual commercial day on tinlarebant opportunity in Stargardt disease type 1
B
BLTE• Commercial day planned for tinlarebant in Stargardt disease type 1
Belite Bio will host a virtual Commercial Day on Sept. 2, 2026, from 8:00 a.m. to 9:30 a.m. ET.
The event will outline the commercial opportunity for tinlarebant in Stargardt disease type 1, contingent on U.S. FDA clearance.
The FDA accepted the tinlarebant NDA for STGD1 with Priority Review; the PDUFA action date is set for Feb. 12, 2027.
